Hofseth Biocare (HBC)

[TekBot]

Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE

Roger Hofseth has today, 6 May 2022, bought 45,000 shares at an average price of
NOK 3.7764 per share. Roger Hofseth is CEO and primary insider of Hofseth
BioCare ASA. After the transaction, Mr. Hofseth owns 200,000 shares privately
…

Vis børsmeldingen

and 51,500,000 shares through his a wholly owned company RH Industri AS,
totalling 51,700,000 shares and corresponding to 14.45 % of the outstanding
shares in Hofseth BioCare ASA.

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act

Kilde

[TekBot]

Hofseth Biocare ASA: CORRECTION: MANDATORY NOTIFICATION OF TRADE

Roger Hofseth has today, 6 May 2022, bought 45,000 shares at an average price of
NOK 3.7764 per share. Roger Hofseth is CEO and primary insider of Hofseth
BioCare ASA. After the transaction, Mr. Hofseth owns 200,000 shares privately
…

Vis børsmeldingen

and 51,500,000 shares through his a wholly owned company RH Industri AS,
totalling 51,700,000 shares and corresponding to 14.45 % of the outstanding
shares in Hofseth BioCare ASA.

Correction: Notification Form

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act

Kilde

[TekBot]

Hofseth Biocare ASA: CONTEMPLATED PRIVATE PLACEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER
JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
…

Vis børsmeldingen

UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE
SECURITIES DESCRIBED HEREIN.

(Ålesund, 1 July 2022) Hofseth Biocare ASA (“HBC” or the “Company”) has resolved
to effect a contemplated private placement of new shares, after the close of
trading on Oslo Børs today (the “Private Placement”).

The Private Placement is directed towards Norwegian and international investors,
subject to applicable exemptions from relevant registration, filing and
prospectus requirements, and subject to other applicable selling restrictions.
The minimum application and allocation amount have been set to the NOK
equivalent of EUR 100,000. The Company may however, at its sole discretion,
allocate amounts below EUR 100,000 to the extent exemptions from the prospectus
requirement in accordance with applicable regulations, including the Norwegian
Securities Trading Act and ancillary regulations, are available.

Through the Private Placement, the Company is offering up to 35,490,000 new
shares (the “Offer Shares”) in the Company to raise gross proceeds of up to NOK
141 million. The subscription price per Offer Share is NOK 4 (the “Offer Price”)
and has been determined based on discussions with the potential subscribers in
the Private Placement. The allocation of Offer Shares in the Private Placement
will be determined by the Company’s board of directors following the application
period. The application period commences today at 16:30 CEST and will close at
08:00 CEST on 4 July 2022. The Company may, however, at its sole discretion,
extend or shorten the application period at any time and for any reason. The
Company will announce the final number of Offer Shares placed in the Private
placement in a stock exchange announcement expected to be published on or about
4 July 2022.

The net proceeds of the Private Placement will be used for general corporate
purposes.

The completion of the Private Placement is subject to; (i) the necessary
corporate resolutions of the Company being made, i.e. approval of the Private
Placement and the allocation of the Offer Shares by the Company’s board of
directors, and (ii) payment of all share deposits and registration with the
Norwegian Register of Business Enterprises of the share capital increase in the
Company pertaining to the Private Placement. The Offer Shares allocated in the
Private Placement will be settled partially through cash payment and partially
through conversion of debt.

CEO Roger Hofseth (through RH Industri AS) and existing shareholders Aqua-Spark
and Bonafide have collectively indicated that they will subscribe for in total
approximately NOK 129 million in the Private Placement.

The Offer Shares allocated in the Private Placement will be settled towards the
investors in the Private Placement as soon as practicable after full payment has
been received and the share capital increase pertaining to the Private Placement
has been registered with the Norwegian Register of Business Enterprises. The
payment date will be on or about 6 July 2022. However, Offer Shares allocated to
Aqua-Spark will be resolved issued through a separate resolution to increase the
share capital, with payment date on or about 24 July 2022. Aqua-Spark will
receive Offer Shares allocated to them as soon as possible after full payment
from Aqua-Spark has been received, and the share capital increase pertaining to
those Offer Shares has been registered. In addition, delivery of Offer Shares
may be made on a delivery versus payment for up to 2 million Offer Shares
through a share lending arrangement between Ødegård Prosjekt AS (a close
associate of CFO Jon Olav Ødegård) and the Company.

The Company’s board of directors has considered the structure of the
contemplated Private Placement in light of the equal treatment obligations under
the Norwegian Securities Trading Act and Oslo Børs’ Circular no. 2/2014 and is
of the opinion that it is in the common interest of the Company and its
shareholders to raise equity through the Private Placement. The existing
shareholders’ preferential rights to subscribe for new shares may be deviated
from. By structuring the equity raise as a private placement, the Company is
expected to raise equity efficiently, with no discount to the current trading
price, at a lower cost and with a significantly lower risk compared to a rights
issue. Further, the Offer Price has been fixed to a premium towards the
prevailing market price of the Company’s shares. Based on the foregoing, it is
currently not planned to conduct a subsequent repair issue directed towards
shareholders not participating in the Private Placement.

Advokatfirmaet CLP DA acts as Norwegian legal counsel in connection with the
Private Placement.

For further information, please contact:

James Berger, CCO at HBC
Phone: +41 79 950 1034
E-mail: jb@hofsethbiocare.no

Jon Olav Ødegård, CFO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

About HBC:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and
the immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD (“smokers lung”) as
well as in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as ‘ProGo’) as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. HBC’s headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto.

HBC is listed on Oslo Børs with ticker “HBC”. More information about HBC at
hofsethbiocare.com and facebook.com/hofsethbiocare.

This information was considered to be inside information pursuant to the EU
Market Abuse Regulation. This stock exchange announcement was published by Jon
Olav Ødegård, Chief Financial Officer, on the time and date provided.

Important information:

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. The
distribution of this announcement and other information may be restricted by law
in certain jurisdictions. Copies of this announcement are not being made and may
not be distributed or sent into any jurisdiction in which such distribution
would be unlawful or would require registration or other measures. Persons into
whose possession this announcement or such other information should come are
required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the “Securities
Act”), and accordingly may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act and in accordance with applicable U.S. state securities laws.
The Company does not intend to register any part of the offering or their
securities in the United States or to conduct a public offering of securities in
the United States. Any sale in the United States of the securities mentioned in
this announcement will be made solely to “qualified institutional buyers” as
defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Regulation” means Regulation 2017/1129 as amended together with any applicable
implementing measures in any Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at “qualified investors” within the meaning of Regulation (EU)
2017/1129 as it forms part of the laws of the United Kingdom by virtue of the
European Union (Withdrawal) Act 2018 (including any statutory instruments made
in exercise of the powers conferred by such act) that are (i) investment
professionals falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high
net worth entities, and other persons to whom this announcement may lawfully be
communicated, falling within Article 49(2)(a) to (d) of the Order (all such
persons together being referred to as “relevant persons”). This communication
must not be acted on or relied on by persons who are not relevant persons. Any
investment or investment activity to which this communication relates is
available only for relevant persons and will be engaged in only with relevant
persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “believe”, “expect”, “anticipate”,
“strategy”, “intends”, “estimate”, “will”, “may”, “continue”, “should” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its control.

Actual events may differ significantly from any anticipated development due to a
number of factors, including without limitation, changes in demand for the
Company’s products, changes in the general economic, political and market
conditions in the markets in which the Company operate, the Company’s ability to
attract, retain and motivate qualified personnel, and changes in laws and
regulation and the potential impact of legal proceedings and actions. Such
risks, uncertainties, contingencies and other important factors could cause
actual events to differ materially from the expectations expressed or implied in
this release by such forward-looking statements. The Company does not provide
any guarantees that the assumptions underlying the forward-looking statements in
this announcement are free from errors nor does it accept any responsibility for
the future accuracy of the opinions expressed in this announcement or any
obligation to update or revise the statements in this announcement to reflect
subsequent events. You should not place undue reliance on the forward-looking
statements in this document.

The information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice. The Company does not undertake any obligation to review, update,
confirm, or to release publicly any revisions to any forward-looking statements
to reflect events that occur or circumstances that arise in relation to the
content of this announcement.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities in the Company. Neither the Company
nor any of its affiliates accept any liability arising from the use of this
announcement.

Kilde

[TekBot]

Hofseth Biocare ASA: PRIVATE PLACEMENT SUCCESSFULLY PLACED

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER
JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
…

Vis børsmeldingen

UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE
SECURITIES DESCRIBED HEREIN.

(Ålesund, 3 July 2022) Reference is made to the stock exchange release from
Hofseth Biocare ASA (“HBC” or the “Company”) published on 1 July 2022 regarding
a contemplated private placement.

The Company hereby announces that it has allocated 35,490,000 new shares in the
Company (the “Offer Shares”) in a private placement (the “Private Placement”) at
a subscription price of NOK 4.00 per Offer Share (the “Offer Price”), thereby
raising gross proceeds of approximately NOK 141 million. The Private Placement
was oversubscribed on the time of completion.

The net proceeds of the Private Placement will be used for general corporate
purposes. The Company is also in the process of securing more fresh salmon raw
material off-cuts from nearby external sources to enable the factory at Midsund
to operate above 80% capacity utilization at all times. The increase in demand
for HBC’s human grade ingredients made from salmon by-products over the past 12
months has increased meaningfully from both the Petcare and nutraceutical
channels. There is now a strong pipeline building for which more consistent raw
materials input is required.

Notification of allotment of the Offer Shares including settlement instructions
will be sent to the applicants through a notification from the Company on or
about 4 July 2022. The Offer Shares will be settled towards the investors in the
Private Placement as soon as practicable after full payment has been received
and the share capital increase pertaining to the Private Placement has been
registered in the Norwegian Register of Business Enterprises. The Offer Shares
allocated in the Private Placement will be settled partially through cash
payment and partially through conversion of debt and outstanding trade credits
(a total of NOK 71,200,760).

In order to increase the share capital pertaining to the Private Placement, the
Company’s board of directors has resolved to issue 35,490,000 new shares in the
Company pursuant to the authorization granted by the Company’s annual general
meeting on 29 April 2022. As disclosed in the stock exchange notice from 1 July
2022, the share capital increase pertaining to the Private Placement has been
divided into two separate resolutions, pursuant to which Aqua-Spark will pay for
shares allocated to it within 24 July 2022. Consequently, the share capital of
the Company will be increased with NOK 354,900. Following registration of the
two resolutions to increase the share capital, the Company will have
393,321,030 shares outstanding, each with a par value of NOK 0.01.

Completion of the Private Placement remains subject to payment of all share
deposits and registration with the Norwegian Register of Business Enterprises of
the share capital increase in the Company pertaining to the Private Placement.

When resolving the issuance of the Offer Shares in the Private Placement, the
Company’s board of directors considered the structure of the Private Placement
in light of the equal treatment obligations under the Norwegian Securities
Trading Act and Oslo Børs’ Circular no. 2/2014 and is of the opinion that it was
in the common interest of the Company and its shareholders to raise equity
through the Private Placement. By structuring the equity raise as a private
placement, the Company was able to raise equity efficiently, with no discount to
the current trading price, at a lower cost and with a significantly lower risk
compared to a rights issue. Further, the Offer Price was fixed to a premium
towards the prevailing market price of the Company’s shares. Based on the
foregoing, it is not planned to conduct a subsequent repair issue directed
towards shareholders not participating in the Private Placement. As a
consequence of the Private Placement structure, the shareholders’ preferential
rights were deviated from.

Advokatfirmaet CLP DA acts as Norwegian legal counsel in connection with the
Private Placement.

For further information, please contact:

Jon Olav Ødegård, CFO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

James Berger, CCO at HBC
Phone: +41 79 950 1034
E-mail: jb@hofsethbiocare.no

About HBC:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD (“smokers lung”) as
well as in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as ‘ProGo’) as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. HBC’s headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto.

HBC is listed on Oslo Børs with ticker “HBC”. More information about HBC at
hofsethbiocare.com and facebook.com/hofsethbiocare.

This information was considered to be inside information pursuant to the EU
Market Abuse Regulation. This stock exchange announcement was published by Jon
Olav Ødegård, Chief Financial Officer, on the time and date provided.

Kilde

[TekBot]

Hofseth Biocare ASA: NOTIFIABLE TRANSACTIONS IN CONNECTION WITH PRIVATE PLACEMENT

Reference is made to the stock exchange notice from Hofseth BioCare ASA (“HBC”
or the “Company”) published on 3 July 2022 regarding the completion of a private
placement raising gross proceeds of approximately NOK 141 million (the "Private
…

Vis børsmeldingen

Placement") through issuance of new shares (the “Offer Shares”) in the Company
with a subscription price of NOK 4 per Offer Share (the “Offer Price”).

The following persons discharging managerial responsibilities and their close
associates have been allocated Offer Shares the Private Placement at the Offer
Price:

i) RH Industri AS, a close associate of CEO Roger Hofseth, has been allocated
17,800,190 Offer Shares, for a total subscription amount of NOK 71,200,760; and
ii) In order to facilitate for partial settlement on a delivery versus payment
basis of Offer Shares in the Private Placement, a share lending agreement has
been entered into between the Company and Ødegård Prosjekt AS (a close associate
of CFO Jon Olav Ødegård). Pursuant to such share lending agreement, Ødegård
Prosjekt AS has agreed to lend 958,810 existing shares in the Company to certain
investors in the Private Placement.

Following the Private Placement, Roger Hofseth and close associates will have a
total holding of 110,825,444 shares and votes in the Company, corresponding to
32.70% of the shares and votes outstanding after the Private Placement.

Please see attached notification forms for further information.

For further information, please contact:

Jon Olav Ødegård, CFO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

James Berger, CCO at HBC
Phone: +41 79 950 1034
E-mail: jb@hofsethbiocare.no

About HBC:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD (“smokers lung”) as
well as in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as ‘ProGo’) as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. HBC’s headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto.

HBC is listed on Oslo Børs with ticker “HBC”. More information about HBC at
hofsethbiocare.com and facebook.com/hofsethbiocare.

This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act
section 5-12.

Kilde

[TekBot]

DISCLOSURE OF LARGE SHAREHOLDING - AQUA-SPARK

Reference is made to the stock exchange announcement by Hofseth BioCare ASA (the
“Company”) on 3 July 2022 regarding completion of a private placement of new
shares (the “Private Placement”). In the Private Placement, the Company will
…

Vis børsmeldingen

issue a total of 35,490,000 new shares.

Aqua-Spark Coöperatieve U.A. applied for and was allocated 10,350,000 shares in
the Private Placement at a price per share of NOK 4. After the issuance of the
new shares in the Private Placement, the shareholding of Aqua-Spark will be more
than 5% of the Company’s share capital.

Following the Private Placement, Aqua-Spark will hold 22,450,000 shares in the
Company, corresponding to 5.71% of the shares and votes outstanding after
completion of the Private Placement.

This information is subject to the disclosure requirements pursuant to Sections
4-2 and 5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED

Ålesund, Norway - 11 July 2022. Reference is made to the stock exchange
announcement on 3 July 2022 regarding the completion of a private placement (the
“Private Placement”) in Hofseth BioCare ASA.
…

Vis børsmeldingen

The share capital increase pertaining to issuance of 25,140,000 of the shares in
the Private Placement (the first resolution, as described in the stock exchange
notice published on 3 July 2022) has now been registered with the Norwegian
Register of Business. The new registered share capital of the Company is NOK
3,829,710.30 divided by 382 971 030 shares, each with a par value of NOK 0.01.

The new shares will be issued in the VPS and delivered to the investors as soon
as practically possible, whereupon the share lending agreement entered into
between Ødegård Prosjekt AS (a close associate of CFO Jon Olav Ødegård) and the
Company in connection with the Private Placement relating to 958,810 of the new
shares, also will be settled.

For further information, please contact:

Jon Olav Ødegård, CFO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Hofseth Biocare ASA: NOTIFIABLE TRANSACTION - REDELIVERY OF SHARES

Reference is made to the stock exchange notice from Hofseth BioCare ASA (“HBC”
or the “Company”) published on 3 July 2022 regarding the completion of a private
placement raising gross proceeds of approximately NOK 141 million through
…

Vis børsmeldingen

issuance of new shares in the Company, and the primary insider notification on
3 July 2022 regarding, inter alia, a share lending agreement between the Company
and Ødegård Prosjekt AS (a close associate of CFO Jon Olav Ødegård). All
958,810 shares lent out from Ødegård Prosjekt AS have now been redelivered to
Ødegård Prosjekt AS.

Further information about the transaction is set out in the attached form.

For further information, please contact:

Jon Olav Ødegård, CFO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act
section 5-12.

Kilde

[TekBot]

Hofseth Biocare ASA: JON OLAV ØDEGÅRD APPOINTED NEW CEO OF HBC

Following years of strong growth in Hofseth International AS (“Hofseth
International”) and the expected further positive development in Hofseth BioCare
ASA’s (“HBC”) revenues and sales activities, it has been decided to strengthen
…

Vis børsmeldingen

management focus in both companies. Roger Hofseth will therefore continue to
serve as CEO of Hofseth International but has decided to step back as CEO of HBC
and change his involvement in the company to a director of the Board, as the
nomination committee has asked the General Assembly to appoint him.

Jon Olav Ødegård, Chief Financial Officer will, with effect from 1 August,
assume the role of CEO. Ødegård has over nine years of executive experience in
the biotechnology industry. Before joining Hofseth BioCare in 2013, Ødegård was
a Managing Director in Sparebank 1 Finans. Previously, he has held executive
positions in Banking and Advisory services. Further he holds several board
positions within the Group of companies that Hofseth BioCare is a part of and
externally in companies such as Aqua Bio Technology ASA.

Kristin Fjellby Grung, Chair of Hofseth BioCare, commented: "Jon brings vast
experience as a leader in the industry with a proven track record. He knows the
company from within and is definitively the right person to continue our mission
to explore the medical and pharmaceutical potential in our products. Hofseth
BioCare has reached a critical phase, demonstrating progress in markets and
development of its enzymatic hydrolysis process, that requires 100% focus on
these activities. The Board is confident that Jon will be the right person to
lead and continue to develop Hofseth BioCare into this phase and the recent
share capital increase secures the necessary funding for continued development.

The Board would like to thank Roger Hofseth for his continued work to build the
Company since the start in 2009. Roger has played a decisive role in
establishing Hofseth BioCare as a supplier of high-value ingredients and
finished products for the nutrition market and his strong involvement in Hofseth
International has secured exclusive long-term access to fresh salmon off-cuts,
providing a competitive edge for HBC."

Jon Olav Ødegård, CEO of Hofseth BioCare commented, “I am very excited to take
on the role as CEO of the Company and look forward to working with the Board and
team to continue the progression of developing our quality nutritional lipids,
proteins and calcium from fresh salmon off-cuts, as well as the hydrolysis
process through further clinical development and ultimately to the patients we
believe will benefit from them.”

Roger Hofseth said: “I have thoroughly enjoyed my past five years as a CEO of
Hofseth BioCare. As the Company progresses through the exciting next steps in
parallel with the strong and very positive development in Hofseth International,
which will be of great importance for HBC going forward, it is a natural time
for me to hand over to Jon who can concentrate fully on HBC’s further
development. I can then concentrate fully on securing vast amounts of fresh
salmon off-cuts from our business in Hofseth International. I will, however,
keenly join the Board if the General Assembly appoints me.”

For further information, please contact:

Kristin Fjellby Grung
Chair of the Board of Hofseth BioCare ASA
Phone: +47 416 55 916
Email: Kristin.Grung@adviso.no (mailto:Kristin.Grung@adviso.no)

About Hofseth BioCare ASA:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new drug leads. Research is ongoing to identify the individual elements
within its ingredients that modulate inflammation and the immune response with
pre-clinical studies in multiple clinics and university research labs in several
countries. Lead clinical and pre-clinical candidates are focused on developing
an oral pharmaceutical lead program to treat inflammatory disease driven by
eosinophils. Preclinical trial work with the oil is ongoing to ameliorate lung
inflammation in eosinophilic asthma and COPD (“smokers lung”) as well as
clinical work in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as ‘ProGo’) as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.
The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of lipids, proteins and calcium from
fresh salmon off-cuts.
Hofseth BioCare’s headquarters are in Ålesund, Norway with branches in Oslo,
London, Zürich, New Jersey, and Palo Alto.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. The stock exchange
announcement was published by Jon Olav Ødegård, CEO of Hofseth BioCare ASA, at
the date and time as set out above.

Kilde

[TekBot]

Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED

In the annual general meeting of Hofseth BioCare ASA (the “Company”) held on 29
April 2022, the general meeting resolved to carry out a private placement
towards Brilliant Invest 2 AG as part of an incentive program for certain
…

Vis børsmeldingen

consultants and partners of the Company. Further, the Company carried out a
private placement towards various investors on 3 July 2022. In the latter
private placement, the payment dates were set in two tranches with the second
tranche having payment date on 24 July 2022.

The share capital increases pertaining to the two private placements mentioned
above have now been registered in the Norwegian Register of Business
Enterprises. The share capital of the Company has increased with NOK 121,100
through the issuance of 12,110,000 new shares, each with a par value of NOK
0.01.

The new registered share capital of the Company is NOK 3,950,810.30 divided by
395,081,030 shares, each with a par value of NOK 0.01.

For further information, please contact:

Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Hofseth Biocare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

An Extraordinary General Meeting of Hofseth BioCare ASA will be held at the
company’s premises at Kipervikgata 13, 6003 Ålesund, on 30 August 2022 at 13:00
CET.
…

Vis børsmeldingen

Please find the notice to the General Meeting attached.

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: joo@hofsethbiocare.no

About Hofseth BioCare ASA

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new drug leads. Research is ongoing to identify the individual elements
within its ingredients that modulate inflammation and the immune response with
pre-clinical studies in multiple clinics and university research labs in several
countries. Lead clinical and pre-clinical candidates are focused on developing
an oral pharmaceutical lead program to treat inflammatory disease driven by
eosinophils. Preclinical trial work with the oil is ongoing to ameliorate lung
inflammation in eosinophilic asthma and COPD (“smokers lung”) as well as
clinical work in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as ‘ProGo’) as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of lipids, proteins and calcium from
fresh salmon off-cuts.

Hofseth BioCare’s headquarters are in Ålesund, Norway with branches in Oslo,
London, Zürich, New Jersey, and Palo Alto.

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act

Kilde

[TekBot]

Hofseth Biocare ASA: SECOND QUARTER & H1 2022 FINANCIAL REPORT

HBC had gross operating revenues of NOK 25.8m (31.0m) in the second quarter. For
the first half of 2022 HBC had revenues of NOK 56.6m (47.9m). Cost of sales
(CoGS) amounted to NOK 17.7m (21.6m) in the quarter. Operating profit (EBITDA)
…

Vis børsmeldingen

for the quarter was NOK -18.3m (-14.6m) and Operating loss (EBIT) amounted to
NOK 26.8m (22.7m) in the second quarter and NOK 60.3m (51.5m) for the first half
of 2022.

Cash flow from operations during the first quarter was NOK -8.8m, compared to
NOK -17.9m in first quarter last year. Net cash flow from investment activities
was NOK -4.6m in the first quarter, compared to NOK -11.5m in the corresponding
quarter last year. Cash flow from financing activities amount­ed to NOK -5.9m in
the first quarter, compared to NOK -4.9m in the first quarter in 2021.

Highlights in the second quarter

• The second quarter was impacted by the constrained supply of salmon-off cuts
  from the price spike in salmon which resulted in unusually low production
  volumes of raw material. However, a very strong demand and favourable market
  prices resulted in net sales of NOK 25m with a gross margin of 31 %,
  compared to 21 % same period last year.
• We successfully completed our second preclinical assay of the bioactive
  peptides in SPH in prostate cancer after publishing the results from our
  first preclinical assay in the journal Marine Drugs. We have demonstrated
  that the addition of the peptides to standard of care enhanced anti-tumor
  activity in drug-sensitive and drug-resistant cell lines.
• Manufacturing optimization of the lead eosinophilia modulating lipopeptide
  MA-022 has been successfully completed. Preclinical trial work with MA-022
  as a drug lead in eosinophilic esophagitis is planned.

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: joo@hofsethbiocare.no (mailto:joo@hofsethbiocare.no)

About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD (“smokers lung”) as
well as in COVID.
Other leads are focused on the protection of the Gastro- Intestinal (GI) system
against inflammation (including ulcerative colitis and the orphan condition
necrotising enterocolitis) and using peptide fractions of salmon protein
hydrolysate (SPH also known as ‘ProGo’) as a Medical Food to help treat age-
related Sarcopenia, and as a treatment for Iron Deficiency Anemia. The company
is founded on the core values of sustainability, optimal utilization of natural
resources and full traceability. Through an innovative hydrolysis technology,
HBC can preserve the quality of the lipids, proteins and calcium from fresh
salmon off-cuts.
Hofseth BioCare’s headquarters are in Ålesund, Norway with branches in Oslo,
London, Zürich, Ningbo, New Jersey and Palo Alto.
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act

Kilde

[TekBot]

Hofseth Biocare ASA: HBC’S PROGO BIOACTIVE PEPTIDES NOW IS A “NEW DIETARY INGREDIENT” (NDI) FOR THE US FDA

Hofseth BioCare ASA is yet again part of an Exclusive Short-List of Companies to
Have Successfully Notified FDA while receiving a No Objection Letter for ProGo®
Bioactive Peptides.
…

Vis børsmeldingen

Summary Highlights of the FDA’s NDI Process for HBC and what it means:

• The FDA’s NDI notification process is the only pre-market gate for
  demonstrating identity, safety, and even cGMP quality for both dietary
  supplements and/or dietary ingredients contained in dietary supplements that are
  new to the US marketplace.
• The NDI letter for ProGo® is the highest safety rating and attestation the
  company could have received from the FDA. This achievement follows on the heels
  of successful receipt of the same accolades for both CalGo® and OmeGo® late last
  year. Today, HBC’s entire portfolio of human food-grade ingredients has received
  FDA’s No Objection Letter, also called an “Acknowledgement Without Comment”
  Letter or Acknowledgement (AKL) Letter.
• The historical acknowledgment rate of NDI notifications by the FDA is low
  (approximately 30%), prompting food companies to choose the easier self-GRAS
  conclusion pathway.
• After rigorous review by FDA scientists (NDI Review Team), ProGo® is permitted
  to deliver up to 24 grams/day in adults (excluding pregnant women),
  significantly in excess of the maximum daily dose used on all the clinical
  trials.

“As a valued client of KGK, HBC has a novel and innovative technology for
extracting nutritional components from Atlantic salmon in a very sustainable
way. The FDA again evaluated that innovative process and the composition of
ProGo® and, in return, has offered the highest safety rating possible. This
acknowledgement AKL letter from FDA speaks to the quality and safety of HBC’s
ProGo®,” said Najla Guthrie, President & Chief Executive Officer of KGK. “These
FDA no-objection letters also help HBC in the global market as many countries
outside of the US are looking for attestation that the FDA has reviewed
nutritional supplements for safety. HBC has navigated that regulatory hurdle and
can check that box,” added Ms. Guthrie.

“ProGo® is permitted to deliver up to 24 grams a day in adults. The FDA’s NDI
process is the highest benchmark of safety that a manufacturer or distributor of
supplements can achieve in the US market. HBC has just distinguished itself from
its competitors, and they demonstrate their commitment to ensuring consumer
confidence with US retailers by navigating FDA’s difficult NDI process. KGK has
significant experience in helping its clients achieve their goals by earning
these high marks of achievement and market distinction,” said Dr. Corey Hilmas,
Chief Regulatory Officer of KGK. “Consumers and retailers are starting to
understand what it means to have an NDI no-objection letter from the FDA. Both
can have confidence that the serving levels in these products are correctly
chosen, based upon appropriate scientific methods and rigorously reviewed by
FDA,” added Dr. Hilmas.

ABOUT HOFSETH BIOCARE
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new drug leads. For new drug leads, research is ongoing to identify the
individual compounds within HBC’s ingredients that modulate inflammation and the
immune response to support and enhance health. Pre-clinical studies are ongoing
both internally in HBCs labs and externally through a number of academic
collaborations. Lead pharmaceutical candidates include an oral analogue to treat
inflammatory disease driven by eosinophils (such as eosinophilic asthma and
eosinophilic esophagitis), and peptides targeting iron metabolism through FTH1,
with prostate cancer one lead indication. For the core nutraceutical business,
clinical trial work with the oil is ongoing to assess its benefit in immune
health and supporting healthy ageing. Clinical trials are also ongoing to assess
our natural collagen-calcium complex in bone and joint health and we plan to
start a clinical trial targeting our ProGo peptides as a medical food for GI
health. This project is led by our collaborator partners at Stanford University
with clinical trial work expected to begin during this year.
The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of lipids, proteins and calcium from
fresh salmon off-cuts.
Hofseth BioCare’s headquarters are in Ålesund, Norway with branches in Oslo,
London, Zürich, Chicago, Palo Alto and Tokyo. Hofseth BioCare’s headquarters are
in Ålesund, Norway with branches in Oslo, London, Zürich, Chicago, Palo Alto and
Tokyo.

ABOUT KGK SCIENCE
Founded in 1997, KGK Science Inc., a subsidiary of Wellbeing Digital Sciences
(NEO: MEDI) (OTC: KONEF) (FRA: SQ2), is a leading North American contract
research organization based in London, Ontario that primarily provides high-
quality clinical research trials with a focus on the nutraceutical, cannabis and
emerging psychedelic industries. The business has successfully helped hundreds
of companies with custom designed clinical trials and claim substantiation
strategies to move products into global markets. KGK’s other existing service
lines include expert regulatory support and compliance solutions, participant
recruitment, research support services and consulting services. On an
approximate basis, the business to date has produced 150 publications, executed
over 400 clinical trials across more than 40 indications, amassed 25,000
participants in its database and collected 10 million data points. For
additional information, please visit kgkscience.com
(https://www.kgkscience.com/).

For further information, please contact:

Wellbeing Digital Sciences & KGK Science Inc.
Natalie Dolphin
VP of Marketing & Investment Relations
Email: ndolphin@wellbeingdigital.co
Twitter: @Wellbeing_IR

Dr. Crawford Currie,
Head of Medical R&D at Hofseth BioCare ASA
Tel: +44 7968 195 497
E-mail: cc@hofsethbiocare.no

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act

Kilde

[TekBot]

Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING

The Extraordinary General Meeting in Hofseth BioCare ASA was held at the
premises of the Company in Ålesund, Norway today Tuesday 30 August 2022.

…

Vis børsmeldingen

All matters were approved according to the proposals in the notice. Please find
the minutes from the general meeting attached.

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: joo@hofsethbiocare.no (mailto:joo@hofsethbiocare.no)

About Hofseth BioCare ASA:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD (“smokers lung”) as
well as in COVID.

Other leads are focused on the protection of the Gastro- Intestinal (GI) system
against inflammation (including ulcerative colitis and the orphan condition
necrotizing enterocolitis) and using peptide fractions of salmon protein
hydrolysate (SPH also known as ‘ProGo’) as a Medical Food to help treat age-
related Sarcopenia, and as a treatment for Iron Deficiency Anemia. The company
is founded on the core values of sustainability, optimal utilization of natural
resources and full traceability. Through an innovative hydrolysis technology,
HBC can preserve the quality of the lipids, proteins and calcium from fresh
salmon off-cuts.

Hofseth BioCare’s headquarters are in Ålesund, Norway with branches in Oslo,
London, Zürich, Ningbo, New Jersey and Palo Alto.

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act

Kilde

[TekBot]

Hofseth Biocare ASA: STANFORD SCHOOL OF MEDICINE SUCCESSFULLY COMPLETES PRE-CLINICAL TRIAL WORK TESTING PROGO® BIOACTIVE PEPTIDES IN EFFECTIVE GUT HEALTH SUPPORT

The study, published in prestigious peer-reviewed journal Biomolecules by MDPI
(Biomolecules | Free Full-Text | Soluble Protein Hydrolysate Ameliorates Gastrointestinal Inflammation and Injury in 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis in Mice | HTML), was conducted through a
collaboration between Hofseth BioCare (HBC) and Stanford University School of
…

Vis børsmeldingen

Medicine. It aimed to further investigate the gastro-intestinal (GI)-protective
properties of the bioactive peptides contained in salmon-derived ProGo®. The
preclinical study found that the soluble protein hydrolysate (SPH) powder,
produced by HBC’s unique enzymatic protein hydrolysis process, helps restore a
healthy balance within the gut immune system and markedly improve gut health in
inflammatory bowel disease (IBD).

The bioactive peptides in SPH significantly reduced colon tissue injury in the
acute colitis animal model by alleviating inflammatory cell infiltrates and
oxidative stress, an underlying driver of many digestive diseases. This points
to ProGo® as having a potential immunomodulatory action through the upregulation
of protective, antioxidant gene pathways including HMOX1.

Prior research undertaken by HBC and Stanford also demonstrated that gene
systems which protect the GI tract against oxidative stress and inflammation are
upregulated in human GI cells exposed to SPH. This latest discovery bolsters
ProGo®’s position as a fresh, effective innovation and presents a prime
opportunity for nutraceutical manufacturers looking to disrupt the gut health
and immunity markets.

“The peptides that constitute ProGo® are proven to not only deliver nutritional
benefits, such as collagen for skin health, but also a myriad of important
health benefits, including antioxidant effects to support gut health and
immunity and to sustain overall health,” said Dr Crawford Currie, Head of
Medical R&D at Hofseth BioCare. “This latest Stanford University study underpins
ProGo®’s reputation as a patented product possessing properties, claims and
health benefits unique to the market. Further clinical studies are in the
pipeline to explore the efficacy of ProGo® as a functional and targeted tool in
IBD management and we look forward to discovering the full potential of this
truly transformative innovation.”

The study adds to the growing bank of evidence demonstrating ProGo® is a pure
and proven product. The ingredient was recently acknowledged as a ‘New Dietary
Ingredient’ (NDI) and secured seven new structure function claims from the US
Food and Drug Administration (FDA). These natural collagen peptides can now also
claim to help “reduce wrinkles and promote skin smoothness”, “help with dry
skin” and “support skin health and appearance”. Furthermore, the evidence of
the peptides’ bioactivity can also now claim to “act and an antioxidant”,
“reduce oxidative stress caused by free radicals” and as well as promoting
energy and sustaining overall health and wellbeing.

To read the full scientific study, click here (https://www.mdpi.com/2218-
273X/12/9/1287/htm), or contact the Hofseth BioCare team: Hofseth BioCare |
Research and development (Hofseth BioCare | Research and development)

About Hofseth BioCare:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new drug leads. Research is ongoing to identify the individual elements
within its ingredients that modulate inflammation and the immune response with
pre-clinical studies in multiple clinics and university research labs in several
countries. Lead clinical and pre-clinical candidates are focused on developing
an oral pharmaceutical lead program to treat inflammatory disease driven by
eosinophils. Clinical trial work to ameliorate lung inflammation in
eosinophilic asthma and COPD (“smokers lung”) is planned and trial work
assessing immune health support is completing in COVID. Other leads are focused
on the protection of the Gastro-Intestinal (GI) system against inflammation
(including ulcerative colitis and the orphan condition necrotising
enterocolitis) and using peptide fractions of salmon protein hydrolysate (SPH
also known as ‘ProGo’) as a Medical Food to help treat age- related Sarcopenia,
and as a treatment for Iron Deficiency Anemia.?

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of lipids, proteins and calcium from
fresh salmon off-cuts. Hofseth BioCare’s headquarters are in Ålesund, Norway
with branches in Oslo, London, Zürich, Chicago, Palo Alto and Tokyo.?

For further information on HBC, please contact:?
Dr. Crawford Currie, Head of Medical R&D?
cc@hofsethbiocare.com (mailto:cc@hofsethbiocare.com) ?

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. The stock exchange
announcement was published by Jon Olav Ødegård, CEO of Hofseth BioCare ASA, at
the date and time as set out above.

Kilde

[TekBot]

Hofseth Biocare ASA: THIRD QUARTER 2022 FINANCIAL REPORT

Highlights in the third quarter

• HBC grew revenue by 105 % year-on-year shows strength of our business in
  …

Vis børsmeldingen

uncertain times and during the third quarter, HBC signed contracts with new
salmon processors to ensure increased access to salmon off-cut for our
production process.

• In July, HBC successfully placed a private placement of 35,490,000 new shares
  at a subscription price of NOK 4.00 per share and raised gross proceeds of NOK
  141 million.
• In August, Mr. Jon Olav Ødegård was appointed CEO by the Board of Directors.
  Mr. Roger Hofseth was elected director to the Board after the general meeting on
  August 30.
• Record organic revenue and profits delivered in Q3 within Consumer and Pet
  health segment with over a fourfold improvement year on year.

Financial update

HBC had gross operating revenues of NOK 30.2m (13.7m) in the third quarter. For
the first nine months of 2022 HBC had revenues of NOK 86.8m (61.5m). Cost of
sales (CoGS) amounted to NOK 24.5m (13.6m) in the quarter. Opex is reduced
throughout the year and also in this quarter from NOK 20m in Q1 2022 to NOK 16m
in the third quarter. Operating profit (EBITDA) for the quarter was NOK -25.4m
(-29.2m) and Operating loss (EBIT) amounted to NOK 33.1m (36.8m) in the third
quarter 2022.

Cash and cash equivalents increased by NOK 40.5m during the quarter, leaving
total holding of cash and cash equivalents at NOK 46.2m by the end of the
period, compared to NOK 85.5m by the end of the third quarter 2021. Including
credit facilities, HBC had NOK 83.2m in free liquidity by the end of the third
quarter 2022.

Commercial update

Q3 saw a normalisation in the price of salmon as expected and this resulted a
progressive recovery in processing volumes and access to salmon off-cuts with
steady improvements HBC production volumes, even in July with the usual shutdown
period. During Q3 we signed contracts with new salmon processors to ensure
increased access to salmon off-cut raw material for our production process.

Our key regions of the UK and US delivered record growth in the quarter driven
by major customer performance, with a focus on e-commerce as a volume lever and
customer marketing tool through use of detailed data analytics and reviews.
Across Europe and Asia the development of landmark private partnership
agreements with major customers and distributors continues apace, with a focus
on these delivering strong margins to support volume growth elsewhere.

R&D update

In the third quarter of 2022, HBC R&D team delivered:

• Following the completion of the preclinical profiling of SPH in protecting the
  gut from intestinal inflammatory damage with our collaborators at Stanford
  University the work has been published in Biomolecules titled “Soluble Protein
  Hydrolysate Ameliorates Gastrointestinal Inflammation and Injury in 2,4,6-
  Trinitobenzene Sulfonic Acid-induced Colitis in Mice”. Planning for clinical
  trial work is ongoing and will be led by Stanford University.

• We have successfully completed our preclinical assay work with the eight
  individual FTH1 peptides in prostate cancer cell lines in combination with
  standard of care androgen deprivation therapy (ADT). This work has identified
  two lead candidates to take forward into in vivo testing. The two individual
  peptides showed markedly greater cancer cell kill rates compared to the whole
  mix of SPH bioactive peptides. This confirms the mode of action to be via FTH1
  and the disruption of iron metabolism within the cancer cell.

• We have been given an oral presentation slot at the Pharma R&D meeting in
  February 2023 for our work in prostate cancer. The presentation will entail all
  the preclinical assay work of the bioactive peptides in SPH in combination with
  androgen deprivation therapy, bicalutamide and enzalutamide (Xtandi), in drug-
  sensitive and drug-resistant prostate cancer cell lines. Other keynote speakers
  include those from major pharmaceutical and biotech companies.

• Preclinical work in restless legs syndrome (RLS / Willis-Ekbom disease)
  continues following the successfully completion of the first assay in human
  skeletal muscle cells with a positive effect on FTH1 gene expression. Similar to
  the prostate cancer work, we plan to identify a lead candidate FTH1 peptide for
  RLS.

• Results from our study of OmeGo® in the management of hospitalised patients
  with Covid will be available during Q4 2022. This will provide a raft of data on
  the impact of OmeGo® in supporting and improving immune health.

• The final House Dust Mite (HDM) allergy preclinical trial with orally
  administered OmeGo® confirms the differentiated and broad anti-inflammatory
  profile of OmeGo®, an important property for optimising health. The results will
  be published in a peer review journal in Q4 2022.

• Manufacturing optimisation of the lead eosinophilia modulating lipopeptide MA-
  022 has been successfully completed. Preclinical trial work with MA-022 as a
  drug lead in eosinophilic esophagitis is planned. Discussions have commenced
  with CDMOs (Contract Drug Manufacturing Organisations) for CMC (chemistry,
  manufacturing and control) dossier development.

• Our clinical trials of CalGo® in bone and joint health are ongoing with data
  expected from the joint health trial during H1 2023. Data from the bone health
  trial is expected during 2024.

• Our asthma study, delineating the immune system benefits from OmeGo, has
  commenced recruitment and we have seen considerable interest from the local
  adult population to participate in the study

Please find the HBC Q3 2022 Financial report attached.

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no (mailto:joo@hofsethbiocare.no)

About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD (“smokers lung”) as
well as in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as ‘ProGo’) as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. Hofseth BioCare’s headquarters are in Ålesund,
Norway with branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto.

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act

Kilde

[TekBot]

Finansiell kalender

Finansiell kalender for Hofseth BioCare ASA

REGNSKAPSÅR 2022
…

Vis børsmeldingen

31.03.2023 - Årsrapport

10.02.2023 - Kvartalsrapport - Q4

REGNSKAPSÅR 2023

25.08.2023 - Halvårsrapport
28.04.2023 - Ordinær generalforsamling

12.05.2023 - Kvartalsrapport - Q1
10.11.2023 - Kvartalsrapport - Q3
09.02.2024 - Kvartalsrapport - Q4

Denne informasjonen offentliggjøres i henhold til kravene i Løpende forpliktelser.

Kilde

[TekBot]

Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE

Ødegård Prosjekt AS, a wholly owned company of Jon Olav Ødegård has today, 30
December 2022, bought 70,000 shares at an average price of NOK 2.91 per share.
Jon Olav Ødegård is CEO and primary insider of Hofseth BioCare ASA.
…

Vis børsmeldingen

After the transaction, Ødegård Prosjekt AS holds 2,964,039 shares, including
860,000 shares held indirectly through ownership in Brilliant Invest AS. Mr.
Ødegård also holds 1,000,000 share options, totalling 4,034,039 shares and share
options corresponding to approx. 1.0 % of the outstanding shares in Hofseth
BioCare ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. The stock exchange
announcement was published by Jon Olav Ødegård, CEO of Hofseth BioCare ASA, at
the date and time as set out above.

Kilde

[Savepig]

Sjefen sjøl

[TekBot]

Hofseth Biocare ASA: FOURTH QUARTER 2022 & FULL YEAR FINANCIAL REPORT

In Q4, the ingredients business continued to show favorable momentum with growth
of 87 %, compared to same quarter last year on an underlying basis, generating
sales revenues of NOK 34m, compared to NOK 18m in the same period last year.
…

Vis børsmeldingen

The finished goods business delivered record fourth quarter and Full Year
revenue and cash margin, with revenue at +68 %, NOK 31.7m, compared to 18.8m in
the same period in 2021, and the fourth quarter alone delivering NOK 10.7m,
compared to 3.7m last year.

HBC has seen a 103 % increase in sales from 31m in the second half of 2021, to
63m in H2 2022. In addition, we have lowered cost base and increased our gross
margins on all products.

Cash flow from operations during the fourth quarter was NOK -5.5m, compared to
NOK -16.2m in fourth quarter last year. Cash and cash equivalents decreased by
NOK 13.8m during the quarter, leaving total holding of cash and cash equivalents
at NOK 69.4m in free liquidity, including credit facility, by the end of 2022.

Highlights in the fourth quarter

• In October, Stanford School of Medicine successfully completed pre-clinical
  trial work testing ProGo bioactive peptides in effective gut health support.
• HBC has hired Mrs. Christel Kanli as new CFO/COO. She has extensive global
  experience from Orkla ASA and several start-ups and will start in March
  2023.
• First significant ProGo order from China for iron deficiency applications
  commenced in Q4 and the pipeline is building.

Please find the HBC Q4 2022 Financial report attached.

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no (mailto:joo@hofsethbiocare.no)

About Hofseth BioCare ASA:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD (“smokers lung”).

Other leads are focused on the protection of the Gastro- Intestinal (GI) system
against inflammation (including ulcerative colitis and the orphan condition
necrotizing enterocolitis) and using peptide fractions of salmon protein
hydrolysate (SPH also known as ‘ProGo’) as a Medical Food to help treat age-
related Sarcopenia, and as a treatment for Iron Deficiency Anemia.

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts.

Hofseth BioCare’s headquarters are in Ålesund, Norway with branches in Oslo,
London, Zürich, Ningbo, New Jersey and Menlo Park, CA.

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act

Kilde